SARS-CoV-2 infection in vulnerable population in Goiania, Central Brazil

Santos, Kamila Cardoso dos; Silva, Grazielle Rosa da Costa e; Moura, Winny Éveny Alves; Magalhães, Larissa Silva; Oliveira, Brunna Rodrigues de; Carvalho, Paulie Marcelly Ribeiro dos Santos; Caetano, Karlla Antonieta Amorim; Carneiro, Megmar Aparecida dos Santos; Pacheco, Leonora Rezende; Borges, Clayton Luiz; Parente-Rocha, Juliana Alves; Bazílio, Gabriela Silvério; Cook, Robert L.; Vaddiparti, Krishna; Rosso, Claci Fátima Weirich; Teles, Sheila Araújo

doi:10.1016/j.jmii.2021.08.005

Cited by 4 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To support this, a strict biosafety infrastructure was created on the university’s premises. Accordingly, a cross-sectional study was carried out between July and October 2020 to investigate SARS-CoV-2 infection in socially vulnerable populations in Goiânia (the capital of the State of Goiás), Central Brazil, as previously described by Santos et al [ 16 ]. Additionally, individuals over the age of 18 were invited to participate in the study.…”

Section: Methodsmentioning

confidence: 99%

Hepatitis E Prevalence in Vulnerable Populations in Goiânia, Central Brazil

Teles,

Caetano,

Carneiro

et al. 2023

Viruses

Self Cite

View full text Add to dashboard Cite

A transversal study was conducted among 472 vulnerable individuals (recyclable waste pickers, immigrants and refugees, homeless individuals, as well as lesbian, gay, bisexual, and transexual individuals) in Goiânia City, the capital of the State of Goiás, Brazil, to investigate the prevalence of hepatitis E virus (HEV) infection. A total of 459 (97.2%) serum samples were tested for anti-HEV IgG and IgM antibodies using fully automated chemiluminescence immunoassays (Liaison® Murex Anti-HEV IgG and IgM assays, DiaSorin, Saluggia, Italy). Positive samples were tested for the presence of HEV RNA by a real-time polymerase chain reaction. A seroprevalence of 0.87% (95% confidence interval [CI]: 0.34–2.22) was found for anti-HEV IgG. Furthermore, anti-HEV IgM was detected in only one individual (0.22%; 95% CI: 0.04–1.22), who was also negative for HEV RNA. These findings revealed that HEV infection is infrequent in vulnerable individuals in Central Brazil, with low seroprevalence of past and recent HEV infections.

show abstract

Section: Methodsmentioning

confidence: 99%

Hepatitis E Prevalence in Vulnerable Populations in Goiânia, Central Brazil

Teles,

Caetano,

Carneiro

et al. 2023

Viruses

Self Cite

View full text Add to dashboard Cite

show abstract

“…Within a very short time, many diagnostic modalities were developed to detect SARS-CoV-2 RNA ( 6 ). According to the World Health Organization (WHO), as of 20 January 2023, there have been 663,640,386 confirmed cases of COVID-19, including multiple waves with different variants around the world ( 2 , 4 , 5 , 7 – 9 ). At present, most reported cases have been identified via the qualitative detection of SARS-CoV-2 RNA, antigens, or antibodies ( 10 – 19 ).…”

Section: Introductionmentioning

confidence: 99%

Performance evaluation of the cobas SARS-CoV-2 Duo, a novel qualitative and quantitative assay, for the detection of SARS-CoV-2 RNA

Su,

Lai,

Lin

et al. 2023

Microbiol Spectr

View full text Add to dashboard Cite

Viral load quantification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a critical measure for monitoring clinical responses of patients with COVID-19. The cobas SARS-CoV-2 Duo (Roche Molecular Systems, Inc.) uses the cobas 6800/8800 platform and is an automated real-time reverse transcription PCR (RT-PCR) assay for the qualitative detection of SARS-CoV-2 RNA (ORF1a and ORF1a/b non-structural regions) in nasal and nasopharyngeal specimens. This assay also performs quantitation of the SARS-CoV-2 RNA level in the collected specimen. The precision, accuracy, and linearity of the cobas SARS-CoV-2 Duo test were assessed and correlated with the cycle threshold (Ct) value of the cobas SARS-CoV-2 assay, and the cobas Liat SARS-CoV-2 and influenza A/B assay (Inf A/B) (cobas Liat) in 201 clinical nasopharyngeal swab specimens. The analytical measurement range of the cobas SARS-CoV-2 Duo has been verified to be 1.0E + 02 IU/mL to 1.0E + 09 IU/mL. The between- and within-run precision evaluation and the linearity results ( R 2 = 0.9961) of the cobas SARS-CoV-2 Duo were acceptable based on the verification criteria. A total of 201 nasopharyngeal specimens were evaluated. The positive, negative, and total agreements between the cobas SARS-CoV-2 Duo and the cobas SARS-CoV-2 assay were 93.5% (157 of 168), 75% (33 of 44), and 92.5% (186 of 201), respectively. The qualitative results (Ct values) from the cobas SARS-CoV-2 and the cobas Liat demonstrated good agreement with the quantitative results from the cobas SARS-CoV-2 Duo assay. In conclusion, the diagnostic performance of the cobas SARS-CoV-2 Duo assay is appropriate. It is a precise, accurate, and sensitive method for the detection of SARS-CoV-2 RNA and is comparable to two qualitative assays. IMPORTANCE Quantitative SARS-CoV-2 tests for viral load are necessary to guide patient treatment, as well as to determine infection control measures and policies. Although the real-time RT-PCR assays can report the Ct value to estimate the viral load, there are several serious concerns regarding the use of Ct values. Importantly, Ct values can vary significantly among between- and within-run methods. The diagnostic performance of the cobas SARS-CoV-2 Duo is appropriate. It is a precise, accurate, and sensitive method for the detection of SARS-CoV-2 RNA and is comparable to two qualitative assays (the cobas SARS-CoV-2 and the Liat cobas SARS-CoV-2 and Inf A/B). In contrast, using the Ct value to estimate viral load is not reliable, and utilization of a quantitative detection test, such as the cobas SARS-CoV-2 Duo, to accurately measure the viral load is needed.

show abstract